

## HEADLINES

### BMRC New Initiative Grants Awarded

The Medical School's Biomedical Research Council (BMRC) recently conducted a competition for New Initiatives Grants for Basic Science Research. The program's goal is to support high-quality scientific projects that are primarily basic science in nature and are specifically aimed at applying innovative ideas or technology to longstanding problems of critical biomedical importance. Congratulations to the four recipients of these \$75,000 awards:

- **Mark Day, Ph.D.**  
Urology  
"BK Virus Induced Hypermethylation in Human Prostate Epithelium"
- **Michael Imperiale, Ph.D.**  
Microbiology and Immunology  
"High Throughput siRNA Screen for Cellular Genes Involved in BKV Infection"
- **Thomas Saunders, Ph.D.**  
Biomedical Research Core Facilities  
"Rat Embryonic Stem Cell Resource for the UM Biomedical Research Community"
- **David L. Turner, Ph.D.**  
Molecular and Behavioral Neuroscience Institute  
"Analysis of Post-transcriptional Gene Regulation in the Mouse Retina"

### BMRC Bridging Support Program for Basic Science Research

#### Extended Deadline: June 15, 2009

The BMRC's Bridging Grant deadline has been extended to **Monday, June 15, 2009**. The extension of this deadline will not impact the review of the grants we have already received.

The Medical School's Biomedical Research Council (BMRC) is accepting applications for a competitive Bridging Support Program for Basic Science Research. This program provides support to bridge federally funded basic science research grants with a very strong demonstrated likelihood of continued federal funding pending resubmission. Up to \$40,000 is available to maintain projects for up to one year. **Matching funds from the PI's department are required.** Eligibility is limited to full-time, on-campus instructional and research faculty with primary appointments in the Medical School. Grants to be bridged must reside in the Medical School. Visit (<http://www.med.umich.edu/medschool/research/support/funding/bridging.htm>) for complete details. For questions, call 734-615-8802 or email (BMRCsubmit@umich.edu).

### UMMS Dean's Faculty Research Awards

#### Deadline: June 12, 2009

#### • **Basic Science Research Award**

The Medical School Dean's Office is soliciting nominations for the Basic Science Research Award. This award recognizes a scientist or group of scientists identified as having made outstanding contributions to the Medical School in basic biomedical science research. The award carries a \$5,000 discretionary academic support prize, which will be given to the faculty member or group.

There is a two-stage selection process. Nominations are reviewed by the Biomedical Research Council, and a list of potential awardees is given to the Dean of the Medical School. The Dean makes the final selection.

**Nominees must be in the rank of Assistant or Associate Professor, or Assistant or Associate Research Professor of the University of Michigan Medical School.** See complete instructions for submission at (<http://www.med.umich.edu/medschool/faculty/facultyawards/basicscience.htm>).

#### • **Clinical & Health Services Research Award**

This award recognizes a faculty member or group of faculty members who are identified as having made outstanding contributions to the Medical School in clinical or health services research. This award carries a \$5,000 discretionary academic support prize, which will be given to the faculty member or group.

There is a two-stage selection process. Nominations submitted to the selection committee will be reviewed and a list of potential awardees given to the Dean of the Medical School. The Dean makes the final selection.

**Nominees must be University of Michigan Medical School faculty at the level of Assistant or Associate Professor, Professor, or Assistant or Associate Clinical Professor, or Clinical Professor.** See complete instructions for submission at (<http://www.med.umich.edu/medschool/faculty/facultyawards/clinicalresearch.htm>).

## RESEARCH COMPLIANCE TRAINING AND EDUCATION

### *Human Research*

#### **When Research Involves Adults with Impaired Decision-Making Capacity**

The University of Michigan policy outlining the requirements applicable when decisionally impaired adults are included in research are found in the Human Research Protection Program (HRPP) Operations Manual (<http://www.research.umich.edu/hrpp/om/>), Part Seven. The category "decisionally impaired" includes not only subjects who have a permanent disability but those whose capacities are

temporally diminished. Investigators need to be aware of and follow this policy, excerpted below.

*From the HRPP Operations Manual, Part 7*

### **Research Involving Adults with Cognitive Impairment or Otherwise Impaired Decision-making Capacity**

Impaired or limited decision-making capacity covers a broad spectrum of conditions. A healthy person in shock may be temporarily decisionally impaired. Another may have been severely mentally retarded since birth, while yet a third who has schizophrenia may have fluctuating capacity.

... The IRB... must evaluate the appropriateness of the research and the adequacy of the investigator's proposed plan for initial and, if applicable, ongoing assessment of participants' capacity to consent. For those participants unable to consent, the IRB must determine whether assent must be secured and, if so, whether the investigator's proposed plan for assent is adequate. The requirement for *assent may be waived by the IRB only if*: (i) the capability of some or all of the subjects is so limited that they cannot reasonably be consulted; (ii) the intervention or procedure holds out the prospect of direct benefit to the health or well-being of the subjects and is available only in the context of the research; or (iii) the research otherwise meets the conditions for waiver of consent consistent with the standards described at 45 C.F.R. §§ 46.116 or 46.117.

An IRB may approve participation of adults with cognitive impairment or diminished decision-making capacity only under the following circumstances:

#### **1. Research Involving No More Than Minimal Risk**

Research involving no more than minimal risk may be approved only if the IRB finds and documents that adequate provisions have been made for soliciting assent from the subject, if appropriate, and permission of the subject's legally authorized representative (e.g., next-of-kin or legal guardian). . . .

#### **2. Research Involving Greater Than Minimal Risk But Presenting the Prospect of Direct Benefit to the Individual Subjects**

Research involving greater than minimal risk may be approved if the IRB finds and documents that:

- The intervention or procedure under investigation holds out the prospect of direct benefit to individual participants, or the monitoring procedure is likely to contribute to the subject's well-being; and
- The risk is justified by the anticipated benefit to participants; and
- The relation of the anticipated benefit to the risk is at least as favorable to participants as that presented by available alternative approaches; and adequate provisions have been made for soliciting assent from the subject and permission from the subject's legally authorized representative (e.g., next-of-kin or legal guardian), or assent is waived consistent with the standards described in 45 C.F.R. § 46.408(a).

### **3. Research Involving Greater Than Minimal Risk and With No Prospect of Direct Benefit to Individual Subjects**

Research that is not approvable under one of the above categories may still be approved by a University IRB if the IRB finds and documents that:

- The research presents a reasonable opportunity to further understanding, prevention, or alleviation of a serious problem affecting the health or welfare of cognitively impaired adults or adults with diminished decision-making capacity;
- Approval is secured from the Institutional Official or Deputy Institutional Official, after consultation with a panel of experts in pertinent disciplines; determination that the research will be conducted consistent with sound ethical principles; and determination that adequate provisions have been made to solicit the assent of the participant and permission of his or her LAR, consistent with the standards described at 45 C.F.R. 46.408(a); and
- Notice of the proposal is posted to the HRPP website (<http://www.research.umich.edu/hrpp/index.html>) for review and comment.

## *Animal Research*

### **Security of Animal Facilities**

The University of Michigan maintains an exemplary animal care and use program of which all of us can be proud. Our animal care and use program maintains full compliance with federal and state regulations and policies, as well as nationally accepted professional standards. Because we are indebted to animals for their valuable contributions to our research and instructional endeavors, and because animal well-being is critical to good science, the University ensures that animals are used in a responsible, respectful, and humane manner.

There are, however, animal activists who disagree with the use of animals in research, teaching, or testing. Some animal activists are prepared to disrupt animal research operations, even if this means violating the law, risking arrest, and going to jail. Because of the potential for activity by animal activists, we should all be alert to maintaining additional security in the animal facilities. The Department of Public Safety recommends that the research community take the following precautions:

- Keep laboratories and offices locked.
- Monitor laboratories and offices for unauthorized persons.
- Wear identification badges at all times.
- **Report suspicious persons, activity, or objects to DPS immediately (Call 911).**
- **Report inquiries regarding building hours, locations of laboratories and offices, type of research being conducted, and location of animals to DPS (734-763-3434).**

Please direct any news media inquiries regarding animal use or care to Kara Gavin, U-M Health System Public Relations, at 734-764-2220. Security concerns regarding the animals or animal facilities should be addressed to the Department of Public Safety and Security at 734-763-3434.

## FREQUENTLY ASKED QUESTIONS

The frequently asked questions (FAQs) highlighted here come from a list of FAQs for research maintained by the Office of Research. To see the complete list, visit (<http://www.med.umich.edu/medschool/research/faq.htm>).

### Q) What type of subject matter can be patented?

A) Patentable subject matter includes processes, machines, compositions of matter, articles, some computer programs, and methods (including methods of making compositions, methods of making articles, and even methods of performing business). A natural substance that has never before been isolated or known may be patentable in some instances, but only in its isolated form (since the isolated form had never been known before). A variation of a naturally occurring substance may be patentable if an inventor is able to demonstrate modifications that offer substantial advantages of using the variant. For more information, contact a U-M Tech Transfer representative through the Tech Transfer website (<http://www.techtransfer.umich.edu/>).

### Q) How do I protect my discovery or invention?

A) Observations and experiments during research activities often lead to new discoveries and inventions. We encourage you to contact U-M Tech Transfer during your early research activities to discuss your options and to provide guidance with respect to the disclosure, evaluation, and protection of your technology. Completing and submitting an Invention Disclosure Form ([http://www.techtransfer.umich.edu/resources/forms\\_documents.php](http://www.techtransfer.umich.edu/resources/forms_documents.php)) will initiate the formal technology transfer process.

The Office of Technology Transfer is the service unit responsible for protecting intellectual property. The Tech Transfer office, along with the Office of the Vice President for Research and General Counsel, contracts with outside patent counsel for intellectual property protection, thus assuring access to patent specialists in diverse technology areas.

## UPDATE FROM WASHINGTON, DC

### White House Releases FY10 Budget Proposal Details – NIH to Receive Small Increase

On May 14, 2009, the Obama Administration released the details of its Fiscal Year 2010 (FY10) Budget Request. Within this request, the National Institutes of Health (NIH) would receive \$538 million – a 1.4% increase over FY09. This small increase reflects the fact that the American Recovery and Reinvestment Act provided at total of \$10.4 billion for the NIH to support research, construction and research equipment. Priority areas include: cancer research, autism research, nanotechnology-related environment, and safety research and bioethics. Specific funding allocations are as follows:

	FY08	FY09 (enacted)	FY10 Request
NCI	\$4.83 billion	\$4.97 billion	\$5.15 billion
NHLBI	\$2.94 billion	\$3.02 billion	\$3.05 billion
NIDCR	\$392 million	\$403 billion	\$408 billion
NIDDK	\$1.87 billion	\$1.91 billion	\$1.93 billion
NINDS	\$1.55 billion	\$1.59 billion	\$1.61 billion

	FY08	FY09 (enacted)	FY10 Request
NIAIDS	\$4.58 billion	\$4.70 billion	\$4.76 billion
NIGMS	\$1.95 billion	\$1.99 billion	\$2.02 billion
NICH5	\$1.26 billion	\$1.29 billion	\$1.31 billion
NEI	\$671 million	\$688 million	\$695.69 million
NIEHS	\$646 million	\$663 million	\$684 million
NIA	\$1.05 billion	\$1.08 billion	\$1.09 billion
NIAMS	\$511 million	\$525 million	\$530.82 million
NIDCD	\$396 million	\$407 million	\$413.03 million
NIMH	\$1.41 billion	\$1.45 billion	\$1.48 billion
NIDA	\$1.01 billion	\$1.03 billion	\$1.04 billion
NIAAA	\$439 million	\$450 million	\$455.15 million
NINR	\$138 million	\$142 million	\$143.7 million
NHGRI	\$489 million	\$502 million	\$509.6 million
NIBIB	\$300 million	\$308 million	\$312.69 million
NCRR	\$1.16 billion	\$1.23 billion	\$1.25 billion
NCCAM	\$122 million	\$125 million	\$127.24 million
NCMHD	\$201 million	\$206 million	\$208.84 million
FIC	\$67 million	\$69 million	\$69.23 million
NLM	\$322 million	\$331 million	\$334.35 million
Office of the Director	\$1.12 billion	\$1.25 billion	\$1.18 billion

An additional \$150 million will go to the Type I Diabetes Initiative. Furthermore, the Budget Request increases the AIDS research program by \$45 million (a 1.5% increase) to \$3.05 billion. NIH also plans to transfer \$300 million to the Global Fund for HIV/AIDS Tuberculosis and Malaria.

With the details of the President's Budget now released, the House and Senate Appropriations committees have begun writing legislation outlining the priorities of the two Chambers of Congress. In some cases, these priorities may significantly differ from the President's proposal. Agreement between Congress and the White House on a final FY10 funding level will be reached near the end of the year. Working with members of the Michigan delegation, U-M will play an active role in the higher education research advocacy efforts on this important topic in the coming months.

## FUNDING/AWARD OPPORTUNITIES

Funding opportunities listed below are for external limited submissions and/or opportunities within the University of Michigan only. To search for other funding and recognition opportunities, visit (<http://www.med.umich.edu/medschool/research/support/funding.htm>). This webpage contains a link to M-Quest (a database of opportunities for grants, honors, prizes and fellowships created and maintained by the Office of Research) as well as information on email alert groups.

### External Limited Submissions

These are opportunities in which the sponsor has limited the number of proposals allowed from an institution. These competitions require an internal review to select the proposals to submit to the sponsor from the University of Michigan.

Abstracts listed here are general information about these funding programs. We strongly urge interested applicants to visit the listed website to verify complete eligibility, program information, and application procedures before submitting an application.

### **Edward Mallinckrodt, Jr. Foundation Grant Program Internal Deadline: June 15, 2009**

The basic aim of the Edward Mallinckrodt, Jr. Foundation is to dispense that amount of yearly income required by law for the purpose of advancing knowledge in the various fields of medical and health research. It is further the general aim to (1) confine contributions to those worthy projects that are in need of initial start-up funding to move the projects forward to the point of other independent support or (2) support highly promising young investigators at the time when start-up funds are limited and initial progress is dependent on additional funding.

It is not the intent to support projects that are already under way and are already receiving significant grant support to provide long-range funding beyond an initial three-year period of support. The Foundation will not fund overhead, and grants will be made and restricted to domestic institutions.

Grants are made in the amount of \$50,000 - \$75,000 per year for a period of one to three years and are contingent upon a yearly progress report by the applicant. The Foundation reviews applications three times a year. The next Foundation deadline is August 1, 2009. **The University of Michigan may submit a maximum of three proposals.**

For consideration as an institutional nominee, submit the following electronically in a single PDF document by **June 15, 2009** to ([limitedsubmissions@umich.edu](mailto:limitedsubmissions@umich.edu)): a 3-page research plan, a NIH formatted biosketch, and a nominating letter from the department chair. **We acknowledge receipt of all electronic submissions. If you do not receive a response from us by the end of the next business day, please call us at 734-763-4086.** Contact Kathryn Ridner at 734-763-4086 or ([kridner@umich.edu](mailto:kridner@umich.edu)) with any questions. Please visit (<http://www.med.umich.edu/medschool/research/support/mallinckrodt.pdf>) for complete Foundation guidelines.

### **Howard Hughes Medical Institute Undergraduate Science Education Program (USEP) – Experiment Grant**

**Internal Deadline: June 15, 2009**

**Foundation Deadline: October 1, 2009**

The Howard Hughes Medical Institute's USEP program has added a new component to their 2010 competition. In addition to their core grant program (Michigan's is headed by Dr. Daniel Klionsky), **UM has been invited to submit one experiment proposal** for the 2010 competition (see details below and on the HHMI website). Experiment Grants are aimed at encouraging science faculty to try innovative ideas in science education.

HHMI-USEP seeks proposals that try nontraditional ways to address challenges in science education – even if the outcome of the experiment is uncertain or there is a significant risk of failure. The proposed experiment should be hypothesis driven, with a rationale based on sound interpretation of available data, and include a careful description of how the results of the experiment will contribute to the understanding of the problem even if the hypothesis is disproved. The proposal should include review

of the relevant prior research, specific strategies for assessing the outcomes of the experiment, and plans for dissemination of findings.

The Office of the Vice President for Research will coordinate the selection process. Please note that the Principal Investigator for the overall Michigan Proposal must be the Principal Investigator on the Core Grant, Dr. Klionsky. But in coordination with Dr. Klionsky, we are searching for the best proposal for the experiment core from across the University.

An Experiment is eligible for funding for up to \$600,000 over four years in addition to the core grant.

If you have an idea for an innovative experiment in undergraduate science education, we are encouraging you to submit your idea to be considered as either the whole or a component of the UM's Experiment Grant. Please submit the following **electronically in a single PDF document to ([OVPRlimitedsubmissions@umich.edu](mailto:OVPRlimitedsubmissions@umich.edu)) by June 15, 2009:**

- 2-page proposal highlighting your hypothesis-driven approach, addressing the degree to which your experiment innovatively and directly addresses one or more important challenges in science education; and your plan for an outcome based assessment of effectiveness.
- An estimated cumulative budget for your experiment.

For full details, including the program announcement, go to (<http://www.hhmi.org/grants/institutions/universities.html>). Direct any questions to Ann Verhey-Henke ([averhey@umich.edu](mailto:averhey@umich.edu)).

### *Internal Submissions*

### **Michigan Metabolomics and Obesity Center Pilot/Feasibility Grant Program Deadline: June 30, 2009 (5:00 PM)**

The goal of the Michigan Metabolomics and Obesity Center (MMOC) is to provide comprehensive phenotyping and computational tools to facilitate and enhance collaborative studies among UM faculty in metabolic diseases, including obesity and related disorders. The MMOC announces a call for proposals to promote interdisciplinary, cross-organizational collaborative research to advance cutting-edge research on nutrition, obesity, and related diseases at the University of Michigan.

The purpose of the MMOC Pilot/Feasibility (P/F) Grant Program is to promote research on the biological and behavioral determinants of obesity, and to develop interventions to reduce obesity and its disease sequelae using basic, clinical, or population approaches. The P/F program's aim is to enable both new and established University of Michigan investigators to generate sufficient preliminary information for a successful application for major research funding from NIH or other national granting agencies.

Grant proposals may be in areas of basic biomedical research or in clinical, epidemiological, or translational research, e.g., interventions in clinical or population-based settings. Animal or human models may be considered. Grant proposals involving cross-disciplinary expertise, faculty from different UM schools, and that utilize the core laboratories of the MMOC are especially encouraged. This call for proposals

*Biomedical News • June 2009*

aims to foster research addressing key questions in the areas of: pathogenesis, diagnosis, prevention, or control of obesity, its complications or related endocrine or metabolic disorders (for example: counter-regulatory proteins, obesity, metabolic syndrome), neuro-peptides which may control eating behavior, adipose tissue biology, gut flora influence on nutrient absorption and cellular functions related to energy utilization.

Individuals who have full-time instructional or research faculty positions at the University of Michigan are eligible to apply as Principal Investigators of P/F proposals. Eligible applicants are: (a) new investigators beginning careers in research on nutrition and obesity; (b) established investigators in areas of biomedical research who wish to focus their expertise on nutrition, obesity and related areas; or (c) established nutritional sciences or obesity investigators who wish to take an entirely **new direction** from their usual work. **This new direction cannot be an extension or outgrowth of research currently being undertaken by the applicant.**

Proposals are for one year of support with funding up to \$50,000. Anticipated funding to begin October 1, 2009. For the application and further instructions, visit the MMOC website (<http://www.med.umich.edu/mmoc/grants>).

### **UM Bone and Joint Injury Prevention and Rehabilitation Center Request for Systematic Review Proposals**

**Deadline: July 15, 2009 (5:00 PM)**

The UM Bone and Joint Injury Prevention and Rehabilitation Center is seeking applications to synthesize our knowledge of anterior cruciate ligament (ACL) injuries by developing systematic reviews of three research topics:

1. The frequency of ACL injuries in the U.S. and their current and projected impact on individual and population health-care costs.
2. The long-term effects and population impact of ACL injuries on the risk of chronic conditions such as post-traumatic osteoarthritis.
3. A description of practices and programs implemented to prevent ACL injuries, and an assessment of their effects in particular target populations.

Applications proposing to conduct one or more of these systematic reviews are solicited. One proposal should be submitted per research topic, even if the same principal investigator submits multiple proposals. The award will be up to \$35,000 per systematic review, and duration of funding is one year.

**Principal investigators must be full-time faculty with 9- or 12-month appointments in the Professor, Research Professor, Research Scientist, or Clinical Professor series at the University of Michigan; and they must be members of the Center.** If not a member of the Center, applicants can become a member by visiting our website at (<http://www.bjiprc.umich.edu/>), clicking on Membership, and applying online.

For complete details including instructions for submission, please visit (<http://www.med.umich.edu/medschool/>

[research/support/bjiprc\\_rfp.pdf](http://www.med.umich.edu/medschool/research/support/bjiprc_rfp.pdf)). Direct inquiries to Ron Zernicke, Director, at 734-930-7070 or ([bjiprc-um@umich.edu](mailto:bjiprc-um@umich.edu)).

### **Michigan Diabetes Research and Training Center (MDRTC) Grant Programs**

**Deadline: August 3, 2009 (5:00 PM)**

Visit (<http://www.med.umich.edu/mdrtc/pilot>) for complete information and application instructions. Contact Pam Campbell, MDRTC at 734-763-5730 or ([pamcamp@umich.edu](mailto:pamcamp@umich.edu)) to obtain an application form.

#### **• Pilot/Feasibility Study Grant Program (MDRTC)**

The Michigan Diabetes Research and Training Center NIH grant supports initiatives by new and established U-M faculty. The goal of this program is to enable investigators to generate a sufficient body of preliminary information for a successful application for major research funding from NIH or other national granting agencies. Grant proposals may be in the areas of basic biomedical research or in clinical, behavioral, epidemiological, health services or translational research. Proposals must address key questions in the pathogenesis, diagnosis, prevention or control of diabetes, its complications, or related endocrine or metabolic disorders. Translational research projects should focus on the translation of research advances into clinical practice and include the identification of barriers to widespread adoption of new science and the testing of interventions to overcome these barriers. Individuals who have full-time instructional or research faculty positions at U-M are eligible to apply as principal investigators. Proposals are for one year of support with funding up to \$50,000.

#### **• Diabetes Interdisciplinary Study Program (MDRTC/MCDC)**

The Michigan Diabetes Research and Training Center and the Michigan Comprehensive Diabetes Center (MCDC) are accepting applications for a pilot and feasibility study to promote interdisciplinary collaboration among researchers. This opportunity promotes collaboration between **two** U-M faculty members from **distinct** disciplines to focus their combined research strengths on cutting-edge areas in diabetes research. Grant proposals may be in areas of basic biomedical research or in clinical, behavioral, epidemiological, health services or translational research. Proposals must address key questions in the pathogenesis, diagnosis, prevention or control of diabetes, its complications, or related endocrine or metabolic disorders. The goal of this program is to enable investigators to generate a sufficient body of preliminary information for a successful application for major research funding from NIH or other national granting agencies. Individuals who have full-time instructional, research or clinical track faculty positions at the U-M are eligible to apply as co-principal investigators. Proposals are for one year of support with funding up to \$100,000.

# UMMS AWARDED GRANTS

## External Awarded Grants

Currently, due to limitations on data collection, we are unable to identify projects awarded with multiple PIs. As the eRPM system is used for proposals in 2009, we will be able to publish those awards accurately. We apologize for any misleading project information this causes.

### Anesthesiology

---

**PI:** Opp, Mark  
**Title:** CYTOKINE AND NEUROTRANSMITTER INTERACTIONS IN SLEEP REGULATION  
**Sponsor:** NIH 1 R01 MH 064843 01 A2  
**Project Dates and Amount of Award:** 04/15/09-03/31/13; \$1,509,773

### Comprehensive Cancer Center

---

**PI:** Jakubowski, Andrzej  
**Title:** MLN4924, A NOVEL INHIBITOR OF NEDD8-ACTIVATING ENZYME, IN ADULT PATIENTS WITH LYMPHOMA OR MULTIPLE MYELOMA (AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY OF)  
**Sponsor:** Millenium Pharm, Inc.  
**Project Dates and Amount of Award:** 02/12/09-02/26/12; \$790,782

**PI:** Smith, David  
**Title:** MLN9708, A SECOND-GENERATION PROTEASOME INHIBITOR, IN ADULT PATIENTS WITH ADVANCED NONHEMATOLOGIC MALIGNANCIES (AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY OF)  
**Sponsor:** Millenium Pharm, Inc.  
**Project Dates and Amount of Award:** 10/07/08-05/31/11; \$1,410,594

**PI:** Wicha, Max  
**Co-I:** Chinnaiyan, Arul (Ctr fr Translational Pathology) / Fearon, Eric (Int Med-Molecular Med&Genetics)  
**Title:** NATIONAL FUNCTIONAL GENOMICS CENTER - A CENTER FOR GENETIC ORIGINS OF CANCER (CGOC) AT THE UNIVERSITY OF MICHIGAN  
**Sponsor:** US DOD-Army, Department of the  
**Project Dates and Amount of Award:** 03/25/09-04/24/10; \$2,036,996

### Human Genetics

---

**PI:** Li, Jun  
**Title:** INTEGRATED GENETIC ANALYSES OF BIPOLAR DISORDER  
**Sponsor:** NARSAD  
**Project Dates and Amount of Award:** 01/01/10-12/31/11; \$60,000

### Internal Medicine

---

**PI:** Bach, David  
**Title:** MANAGEMENT IMPACT OF CLINICAL REMINDERS ATTACHED TO ECHOCARDIOGRAPHY REPORTS AMONG PATIENTS WITH SEVERE AORTIC STENOSIS  
**Sponsor:** Edwards Lifesciences Llc  
**Project Dates and Amount of Award:** 10/01/08-12/31/11; \$43,923

**PI:** Bagwe, Suveer  
**Title:** 2009 EP FELLOWSHIP PROGRAM  
**Sponsor:** Medtronic, Inc.  
**Project Dates and Amount of Award:** 07/01/09-06/30/10; \$40,000

**PI:** Bradley, Deborah  
**Title:** NEOADJUVANT GEMCITABINE, CISPLATIN AND CETUXIMAB FOR MUSCLE INVASIVE BLADDER CANCER, A PHASE II TRIAL OF  
**Sponsor:** Hope Foundation, The  
**Project Dates and Amount of Award:** 07/01/09-06/30/11; \$100,000

**PI:** Donato, Nicholas  
**Title:** ASSESSMENT OF PS-H3 ASSAY FOR DETECTION OF TAK-901 PHARMACODYNAMIC ACTIVITY  
**Sponsor:** Millenium Pharm, Inc.  
**Project Dates and Amount of Award:** 05/01/09-08/31/09; \$14,006

**PI:** Eagle, Kim  
**Title:** PROJECT HEALTHY SCHOOLS, A COMMUNITY-UNIVERSITY COLLABORATIVE BETWEEN ANN ARBOR, MI AND THE U OF M  
**Sponsor:** Atkins, Robert C. Dr., & Veronica, Foundation  
**Project Dates and Amount of Award:** 01/01/09-01/01/11; \$150,000

**PI:** Kumar, Sanjeev  
**Title:** COMBINING AN MDM2 INHIBITOR WITH CHEMOTHERAPY FOR THE TREATMENT OF MELANOMA  
**Sponsor:** Melanoma Research Alliance (MRA)  
**Project Dates and Amount of Award:** 06/01/09-05/31/11; \$100,000

**PI:** Pelosi Jr, Frank  
**Title:** 2009 EP FELLOWSHIP PROGRAM  
**Sponsor:** Biosense Webster, Inc.  
**Project Dates and Amount of Award:** 07/01/09-06/30/10; \$50,000

**PI:** Rabquer, Bradley  
**Title:** CONTRIBUTION OF SOLUBLE JUNCTIONAL ADHESION MOLECULES TO ANGIOGENESIS  
**Sponsor:** NIH 1 F32 HL 094017 01 A1  
**Project Dates and Amount of Award:** 05/01/09-04/30/12; \$155,118

**PI:** Rosenson, Robert  
**Title:** MIPOMERSEN IN PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA ON A MAXIMALLY TOLERATED LIPID LOWERING REGIMEN AND WHO ARE NOT ON APHERESIS (A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF)  
**Sponsor:** Genzyme Corporation TO Medpace, Inc.  
**Project Dates and Amount of Award:** 04/06/09-02/28/10; \$81,100

**PI:** Saini, Sameer  
**Title:** UTILIZATION OF GASTROPROTECTIVE AGENTS IN AT-RISK PATIENTS UNDERGOING PCI (PERCUTANEOUS CORONARY INTERVENTION) RECEIVING MULTIPLE ANTIPLATELET AGENTS  
**Sponsor:** AstraZeneca plc  
**Project Dates and Amount of Award:** 03/25/09-03/24/10; \$39,998

**PI:** Seibold, James  
**Co-I:** Schiopu, Elena (Int Med-Rheumatology)  
**Title:** DISTOL-1: DIGITAL ISCHEMIC LESIONS IN SCLERODERMA TREATED WITH ORAL TREPROSTINIL DIETHANOLAMINE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY  
**Sponsor:** United Therapeutics Corp  
**Project Dates and Amount of Award:** 03/13/09-01/31/11; \$106,538

**PI:** Zimmermann, Ellen  
**Title:** GI FELLOW EDUCATIONAL SUPPORT  
**Sponsor:** Santarus, Inc.  
**Project Dates and Amount of Award:** 04/01/09-12/31/09; \$1,950

### Microbiology and Immunology

---

**PI:** Wobus, Christiane  
**Title:** IDENTIFICATION OF SMALL MOLECULE INHIBITORS AND NOVEL DRUG TARGETS FOR NOROVIRUSES  
**Sponsor:** NIH - Subcontracts TO University of Chicago U54 AI 057153  
**Project Dates and Amount of Award:** 03/24/09-02/28/10; \$177,675

### Molecular & Integrative Physiology

---

**PI:** Schwartz, Jessica  
**Title:** C/EBPB AND HETEROCHROMATIN: THEIR ROLE IN ADIPOGENESIS  
**Sponsor:** NIH 1 R03 TW 008143 01 A1  
**Project Dates and Amount of Award:** 04/08/09-03/31/12; \$103,432

### Neurology

---

**PI:** Cheng, Hsinlin  
**Co-I:** Feldman, Eva (Neurology Department)  
**Title:** NERVE GROWTH FACTOR SIGNALING IN PAINFUL DIABETIC NEUROPATHY  
**Sponsor:** NIH 1 K08 NS 061039 01 A2  
**Project Dates and Amount of Award:** 04/15/09-03/31/14; \$866,700

**PI:** Chou, Kelvin  
**Title:** THREE DOSES OF APLINDORE MR (1.3, AND 6MG TWICE DAILY) IN PATIENTS WITH EARLY PARKINSON DISEASE (A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF)  
**Sponsor:** Neurogen Corporation TO University of Rochester  
**Project Dates and Amount of Award:** 10/01/08-10/31/09; \$71,650

**PI:** Rusche-Skolarus, Lesli  
**Co-I:** Brown, Devin (Neurology Department)  
**Title:** SLEEP APNEA IN MEXICAN AMERICAN AND NON-HISPANIC WHITE STROKE PATIENTS  
**Sponsor:** American Academy of Neurology  
**Project Dates and Amount of Award:** 09/01/09-06/30/11; \$130,000

## Ophthalmology & Visual Sciences

---

**PI:** Stein, Joshua  
**Title:** THE ASSOCIATION BETWEEN CATARACT SURGERY AND PROGRESSION OF DIABETIC RETINOPATHY  
**Sponsor:** NIH 1 K23 EY 019511 01  
**Project Dates and Amount of Award:** 05/01/09-04/30/14; \$1,038,335

**PI:** Wu, David  
**Title:** THE PHYSIOLOGY OF THE EARLY POSTNATAL RETINAL MICROVESSELS AND IMPLICATIONS FOR RETINOPATHY OF PREMATURITY  
**Sponsor:** Knights Templar Eye Foundation  
**Project Dates and Amount of Award:** 07/01/09-06/30/10; \$40,000

## Pathology

---

**PI:** Chinnaiyan, Arul  
**Title:** DEVELOPMENT OF "ONCOSEQ", A BIOINFORMATICS PLATFORM FOR NEXTGEN SEQUENCING IN ONCOLOGY  
**Sponsor:** American Cancer Society  
**Project Dates and Amount of Award:** 07/01/09-06/30/14; \$400,000

**PI:** Elenitoba-Johnson, Kojo  
**Co-I:** Chey, William (Int Med-Gastroenterology) / Lim, Megan (Pathology Department) / Mcallister-Lucas, Linda (Pediatrics-Hematology / Oncology) / Nesvizhskii, Alexey (Pathology Department)  
**Title:** PROTEOMIC ANALYSIS OF API2-MALT1 POSITIVE GASTRIC MALT LYMPHOMA  
**Sponsor:** NIH 1 R01 CA 136905 01  
**Project Dates and Amount of Award:** 03/26/09-01/31/14; \$1,436,205

**PI:** Smith, Douglas  
**Title:** DNA SAMPLES FOR THE CHARACTERIZATION OF SWINE LEUKOCYTE ANTIGENS  
**Sponsor:** Spring Point  
**Project Dates and Amount of Award:** 03/31/09-04/01/11; \$10,000

## Pediatrics & Communicable Diseases

---

**PI:** Ferrara, James  
**Title:** A BIOENERGETIC STRATEGY TO TREAT GRAFT VERSUS HOST DISEASE  
**Sponsor:** Hartwell Foundation  
**Project Dates and Amount of Award:** 04/01/09-03/31/12; \$300,000

**PI:** Fredericks, Emily  
**Title:** FUNCTIONAL OUTCOMES OF PEDIATRIC LIVER TRANSPLANTATION  
**Sponsor:** NIH - Subcontracts TO Children's Memorial Hospital R01 HD 045694  
**Project Dates and Amount of Award:** 04/01/09-03/31/10; \$21,750

**PI:** Kitko, Carrie  
**Title:** FEASIBILITY ASSESSMENT AGREEMENT  
**Sponsor:** Therakos, Inc.  
**Project Dates and Amount of Award:** 03/01/09-02/28/10; \$7,800

## Pharmacology

---

**PI:** Anantharam, Arun  
**Title:** SECRETION-ASSOCIATED DYNAMICS OF THE PLASMA MEMBRANE  
**Sponsor:** NIH 1 F32 GM 086169 01 A1  
**Project Dates and Amount of Award:** 07/01/09-06/30/11; \$96,472

## Physical Medicine & Rehabilitation

---

**PI:** Tate, Denise  
**Co-I:** Meade, Michelle (Physical Medicine & Rehab Dept) / Miller, Sonya (Physical Medicine & Rehab Dept)  
**Title:** UNIVERSITY OF MICHIGAN HEALTH SYSTEM (UMHS) / ANN ARBOR CENTER FOR INDEPENDENT LIVING (AACIL) REHABILITATION RESEARCH TRAINING PROGRAM  
**Sponsor:** U.S. Department Of Education  
**Project Dates and Amount of Award:** 09/01/09-08/31/14; \$749,775

## Psychiatry

---

**PI:** Buu, Yuh-Pey  
**Title:** NEW STATISTICAL METHODOLOGY TO ESTABLISH CONSTRUCT VALIDITY FOR CHILDHOOD RISK  
**Sponsor:** NIH 1 K01 AA 016591 01 A2  
**Project Dates and Amount of Award:** 04/10/09-03/31/14; \$791,249

**PI:** Zucker, Robert  
**Co-I:** Burmeister, Margit (Molecular & Behav Neurosc Inst) / Heitzeg, Mary (Psych Substance Abuse) / Long, Jeffrey (Human Genetics Department) / Noll, Douglas (Biomedical Engineering) / Shedden, Kerby (LSA Statistics) / Zubieta, Jon (Molecular & Behav Neurosc Inst)

**Title:** BRAIN ENDOPHENOTYPES MODULATING DRUG ABUSE RISK (FEB 2008 EPAF 1 OF 2)  
**Sponsor:** NIH 1 R01 DA 027261 01  
**Project Dates and Amount of Award:** 04/15/09-03/31/14; \$3,264,330

## Radiation Oncology

---

**PI:** Jagsi, Reshma  
**Co-I:** Moran, Jean (Radiation Oncology - Ann Arbor)  
**Title:** PATIENT EXPECTATIONS, EXPERIENCES, AND OUTCOMES IN A RANDOMIZED TRIAL COMPARING IMRT TO CONFORMAL RADIOTHERAPY FOR BREAST CANCER  
**Sponsor:** American Cancer Society  
**Project Dates and Amount of Award:** 07/01/09-06/30/13; \$580,000

## Radiology

---

**PI:** Agarwal, Prachi  
**Co-I:** Carlos, Ruth (Radiology Department) / Cronin, Paul (Radiology Department) / Kazerooni, Ella (Radiology Department) / Rubenfire, Melvyn (Int Med-Cardiology) / Starling, John (Dermatology Department)  
**Title:** PREMATURE CORONARY ARTERY DISEASE IN SEVERE PSORIASIS  
**Sponsor:** National Psoriasis Foundation  
**Project Dates and Amount of Award:** 04/15/09-04/14/10; \$50,000

**PI:** Meyer, Charles  
**Co-I:** Bland, Peyton (Radiology Department) / Chenevert, Thomas (Radiology Department) / Fessler, Jeffrey (Elec Engr & Comp Sci) / Helvie, Mark (Radiology Department) / Hero Iii, Alfred (Elec Engr & Comp Sci) / Johnson, Timothy (Biostatistics Department) / Kim, Boklye (Radiology Department) / Kim, Sinae (Biostatistics Department) / Kluin, Karen (Neurology Department) / Ma, Bing (Radiology Department) / Newman, Lisa (General Surgery Section) / Parent, Jack (Neurology Department) / Park, Hyunjin (Radiology Department) / Ross, Brian (Radiology Department) / Sagher, Oren (Neurosurgery) / Schott, Anne (Int Med-Hematology/Oncology) / Scott, Clayton (Elec Engr & Comp Sci) / Visscher, Daniel (Pathology Department) / Wakin, Michael (Elec Engr & Comp Sci)  
**Title:** AUTOMATIC THREE DIMENSIONAL (3D) REGISTRATION FOR ENHANCED CANCER MANAGEMENT  
**Sponsor:** NIH 2 P01 CA 087634 06 A2  
**Project Dates and Amount of Award:** 04/09/09-02/28/14; \$7,518,481

**PI:** Williams, David  
**Co-I:** Cho, Kyung (Radiology Department) / Cwikiel, Wojciech (Radiology Department) / Dasika, Narasimham (Radiology Department) / Eliason, Jonathan (Vascular Surgery Section) / Gemmete, Joseph (Radiology Department) / Krishnamurthy, Venkataramu (Radiology Department) / Novelli, Paula (Radiology Department) / Rectenwald, John (Vascular Surgery Section) / Shields, James (Radiology Department) / Upchurch Jr, Gilbert (Vascular Surgery Section) / Vellody, Ranjith (Radiology Department)  
**Title:** EPIC NITINOL STENT SYSTEM IN THE TREATMENT OF ATHEROSCLEROTIC LESIONS IN ILIAC ARTERIES (ORION)  
**Sponsor:** Boston Scientific Corporation  
**Project Dates and Amount of Award:** 04/07/09-04/06/15; \$132,850

## Surgery

---

**PI:** Si, Ming-Sing  
**Title:** UTILIZING THYMUS-DERIVED MESENCHYMAL STEM CELLS FOR BIOENGINEERED HEART MUSCLE IN PEDIATRIC CARDIAC SURGERY  
**Sponsor:** American Medical Association Foundation  
**Project Dates and Amount of Award:** 01/01/09-12/01/09; \$2,388

**PI:** Upchurch Jr, Gilbert  
**Title:** THRIVE: DESCENDING THORACIC AORTIC ANEURYSM ENDOVASCULAR REPAIR POST APPROVAL STUDY  
**Sponsor:** Medtronic, Inc.  
**Project Dates and Amount of Award:** 04/13/09-04/30/14; \$41,700

## Urology

---

**PI:** Keller, Evan  
**Title:** NOVEL APTAMERS TO TARGET METASTASIS  
**Sponsor:** US DOD-Army, Department of the  
**Project Dates and Amount of Award:** 09/01/09-11/30/12; \$567,231

# UMMS RESEARCH PUBLICATIONS

## Biological Chemistry

Bertelsen EB, Chang L, Gestwicki JE, Zuiderweg ER. Solution conformation of wild-type E. coli Hsp70 (DnaK) chaperone complexed with ADP and substrate. *Proc Natl Acad Sci USA*. 2009 May 13 (Epub ahead of print).

Bhattacharya A, Kurochkin AV, Yip GN, Zhang Y, Bertelsen EB, Zuiderweg ER. Allosteric in Hsp70 chaperones is transduced by subdomain rotations. *J Mol Biol*. 2009 May 8; 388(3): 475-90.

Bommiasamy H, Back SH, Fagone P, Lee K, Meshinchi S, Vink E, Sriburi R, Frank M, Jackowski S, Kaufman RJ, Brewer JW. ATF6[alpha] induces XBP1-independent expansion of the endoplasmic reticulum. *J Cell Sci*. 2009 May 15; 122(Pt 10): 1626-36.

Brinkmeier ML, Davis SW, Carninci P, Macdonald JW, Kawai J, Ghosh D, Hayashizaki Y, Lyons RH, Camper SA. Discovery of transcriptional regulators and signaling pathways in the developing pituitary gland by bioinformatic and genomic approaches. *Genomics*. 2009 May; 93(5): 449-60.

Chiku T, Padovani D, Zhu W, Singh S, Vitvitsky V, Banerjee R. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia. *J Biol Chem*. 2009 Apr 24; 284(17): 11601-12.

Coughlin DJ, Babak T, Nihranz C, Hughes TR, Engelke DR. Prediction and verification of mouse tRNA gene families. *RNA Biol*. 2009 Apr 31; 6(2) (Epub ahead of print).

Davies MJ, Miranda E, Roussel BD, Kaufman RJ, Marciniak SJ, Lomas DA. Neuroserpin polymers activate NF-kappaB by a calcium signalling pathway that is independent of the unfolded protein response. *J Biol Chem*. 2009 May 7 (Epub ahead of print).

Davis SW, Potok MA, Brinkmeier ML, Carninci P, Lyons RH, MacDonald JW, Fleming MI, Mortensen AH, Egashira N, Ghosh D, Steel KP, Osamura RY, Hayashizaki Y, Camper SA. Genetics, gene expression and bioinformatics of the pituitary gland. *Horm Res*. 2009 Apr; 71 Suppl 2: 101-15.

Galbán CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Ross DJ, Rehemtulla A, Ross BD. The parametric response map is an imaging biomarker for early cancer treatment outcome. *Nat Med*. 2009 May; 15(5): 572-6.

Grahn EM, Winter HC, Tateno H, Goldstein IJ, Krengel U. Structural Characterization of a Lectin from the Mushroom *Marasmius oreades* in Complex with the Blood Group B Trisaccharide and Calcium. *J Mol Biol*. 2009 May 5 (Epub ahead of print).

Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R, Guan KL, Yoshimura A. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. *Biochem Biophys Res Commun*. 2009 May 5 (Epub ahead of print).

Nacionales DC, Weinstein JS, Yan XJ, Albesiano E, Lee PY, Kelly-Scumpia KM, Lyons R, Satoh M, Chiorazzi N, Reeves WH. B cell proliferation, somatic hypermutation, class switch recombination, and autoantibody production in ectopic lymphoid tissue in murine lupus. *J Immunol*. 2009 Apr 1; 182(7): 4226-36.

Padovani D, Banerjee R. A Rotary Mechanism for Coenzyme B<sub>12</sub> Synthesis by Adenosyltransferase. *Biochemistry*. 2009 May 4 (Epub ahead of print).

Singh S, Madzlan P, Stasser J, Weeks CL, Becker D, Spiro TG, Penner-Hahn J, Banerjee R. Modulation of the heme electronic structure and cystathionine beta-synthase activity by second coordination sphere ligands: The role of heme ligand switching in redox regulation. *J Inorg Biochem*. 2009 May; 103(5): 689-97.

Suh N, Crittenden SL, Goldstrosch A, Hook B, Thompson B, Wickens M, Kimble J. FBF and its dual control of *gld-1* expression in the *Caenorhabditis elegans* germline. *Genetics*. 2009 Apr; 181(4): 1249-60.

Takahashi YH, Lee JS, Swanson SK, Saraf A, Florens L, Washburn MP, Trievel RC, Shilatifard A. Regulation of H3K4 trimethylation via Cps40 (Spp1) of COMPASS is monoubiquitination-independent: Implication for a Phe/Tyr switch by the catalytic domain of Set1. *Mol Cell Biol*. 2009 Apr 27 (Epub ahead of print).

Tran TT, Starnes V, Wang X, Getzen J, Ross BD. Cardiovascular magnetic resonance diagnosis of cystic tumor of the atrioventricular node. *J Cardiovasc Magn Reson*. 2009 Apr 30; 11(1): 13.

Umemori H. Weaving the neuronal net with target-derived fibroblast growth factors. *Dev Growth Differ*. 2009 Apr; 51(3): 263-70.

## Family Medicine

Aikens JE, White Perkins D, Lipton B, Piette JD. Longitudinal analysis of depressive symptoms and glycaemic control in type 2 diabetes. *Diabetes Care*. 2009 Apr 23 (Epub ahead of print).

Green LA, Frey KA, Froehlich JB, Harrison RV, Kleaveland MD, Kronick S, Williams DM, Weg JG, Wakefield TW. Venous thromboembolism (update). Ann Arbor, MI: Faculty Group Practice, University of Michigan Health System, 2008. (Practice guideline -- available from the Agency for Healthcare Research and Quality at (<http://www.guideline.gov/>)).

Jimbo M, Barrie WE, Dorsch MP, Harrison RV, Jamerson KA. Essential Hypertension. Ann Arbor, MI: Office of Clinical Affairs, University of Michigan Health System, 2009. (Practice guideline -- available from the Agency for Healthcare Research and Quality at (<http://www.guideline.gov/>)).

## Human Genetics

Dyson G, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A, Sing CF. Modifications to the Patient Rule-Induction Method that utilize non-additive combinations of genetic and environmental effects to define partitions that predict ischemic heart disease. *Genet Epidemiol*. 2009 May; 33(4): 317-24.

Huang Y, Giblin W, Kubec M, Westfield G, St Charles J, Chadde L, Kraftson S, Sekiguchi J. Impact of a hypomorphic Artemis disease allele on lymphocyte development, DNA end processing, and genome stability. *J Exp Med*. 2009 Apr 13; 206(4): 893-908.

Marvin ML, Bradford CR, Sisson JC, Gruber SB. Diagnosis and management of hereditary paraganglioma syndrome due to the F933>X67 SDHD mutation. *Head Neck*. 2009 May; 31(5): 689-94.

Sharkey LM, Jones JM, Hedera P, Meisler MH. Evaluation of SCN8A as a candidate gene for autosomal dominant essential tremor. *Parkinsonism Relat Disord*. 2009 May; 15(4): 321-3.

Vilar E, Mukherjee B, Kuick R, Raskin L, Misesk DE, Taylor JM, Giordano TJ, Hanash SM, Fearon ER, Rennert G, Gruber SB. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. *Clin Cancer Res*. 2009 Apr 15; 15(8): 2829-39.

Zöllner S, Su G, Stewart WC, Chen Y, McInnis MG, Burmeister M. Bayesian EM algorithm for scoring polymorphic deletions from SNP data and application to a common CNV on 8q24. *Genet Epidemiol*. 2009 May; 33(4): 357-68.

## Internal Medicine

### Infectious Diseases:

Cober ED, Malani PN. Clostridium Difficile Infection in the "Oldest" Old: Clinical Outcomes in Patients Aged 80 and Older. *J Am Geriatr Soc*. 2009; 57(4): 659-662.

Eyler RF, Butler SO, Walker PC, DePestel DD, Spoor MT, Pagani FD, Malani PN. Vancomycin Use During Left Ventricular Assist Device Support. *Infect Contr Hosp Epidemiol*. 2009; 30(5): 484-486.

Stapleford KA, Rapaport D, Miller DJ. Mitochondrion-Enriched Anionic Phospholipids Facilitate Flock House Virus RNA Polymerase Membrane Association. *J Virol*. 2009; 83(9): 4498-4507.

### Microbiology and Immunology

Eaton KA. Trends in the oral healthcare workforce and the delivery of care and their implications. *Prim Dent Care*. 2009 Apr; 16(2): 43-4.

Goldman DL, Huffnagle GB. Potential contribution of fungal infection and colonization to the development of allergy. *Med Mycol*. 2009 Apr 22: 1-12.

Hogue IB, Hoppe A, Ono A. Quantitative FRET Microscopy Analysis of HIV-1 Gag-Gag Interaction: The Relative Contributions of CA and NC Domains, and Membrane Binding. *J Virol*. 2009 Apr 29 (Epub ahead of print).

Hu PJ, Sherman DH. DANCing with *Caenorhabditis elegans*. *Proc Natl Acad Sci USA*. 2009 May 5 (Epub ahead of print).

Li S, Anzai Y, Kinoshita K, Kato F, Sherman DH. Functional Analysis of MycE and MycF, Two O-Methyltransferases Involved in the Biosynthesis of Mycinamicin Macrolide Antibiotics. *Chembiochem*. 2009 May 4 (Epub ahead of print).

O'Malley HA, Shreiner AB, Chen GH, Huffnagle GB, Isom LL. Loss of Na<sup>+</sup> channel beta2 subunits is neuroprotective in a mouse model of multiple sclerosis. *Mol Cell Neurosci*. 2009 Feb; 40(2): 143-55.

O'May GA, Jacobsen SM, Longwell M, Stoodley P, Mobley HL, Shirliff ME. The high-affinity phosphate transporter Pst in *Proteus mirabilis* HI4320 and its importance in biofilm formation. *Microbiology*. 2009 May; 155(Pt 5): 1523-35.

Park SH, Choi SS, Kim YJ, Chang YK, Sherman DH, Kim ES. Functional expression of SCO7832 stimulates tautomycin production via pathway-specific regulatory gene overexpression in *Streptomyces* sp. CK4412. *J Ind Microbiol Biotechnol*. 2009 May 1 (Epub ahead of print).



## Neurology

Bogaard A, Parent J, Zochowski M, Booth V. Interaction of cellular and network mechanisms in spatiotemporal pattern formation in neuronal networks. *J Neurosci*. 2009 Feb 11; 29(6): 1677-87.

Chirakalwasan N, Hassan F, Kaplish N, Fetterolf J, Chervin RD. Near resolution of sleep related rhythmic movement disorder after CPAP for OSA. *Sleep Med* 2009; 10: 497-500.

Irani DN, Prow NA. Host responses during Sindbis virus encephalomyelitis in mice: New implications for understanding the pathogenesis of alphavirus infections of the central nervous system. In: Yang D, editor. *RNA Viruses: Host Gene Responses to Infections*. Singapore: World Scientific Press; 2009. p. 601-623.

Ouyang F, Lu BS, Wang B, Wang H, Yang J, Li Z, Wang L, Tang G, Xing H, Xu X, Chervin RD, Zee PC, Wang X. Sleep patterns and influencing factors among rural Chinese adolescents. *Sleep Med* 2009; 10: 479-489.

Singer BH, Jutkiewicz EM, Fuller CL, Lichtenwalner RJ, Zhang H, Velander AJ, Li X, Gnegy ME, Burant CF, Parent JM. Conditional ablation and recovery of forebrain neurogenesis in the mouse. *J Comp Neurol*. 2009 Jun 20; 514(6): 567-82.

Teodorescu M, Consens FB, Bria WF, Coffey MJ, McMorris MS, Weatherwax KJ, Palmisano J, Senger CM, Ye Y, Kalbfleisch JD, Chervin RD. Predictors of habitual snoring and obstructive sleep apnea risk in patients with asthma. *Chest* 2009; 135: 1125-1132.

## Neurosurgery

Allen J, Donahue B, Mehta M, Miller DC, Rorke LB, Jakacki R, Robertson P, Sposto R, Holmes E, Vezina G, Muraszko K, Puccetti D, Prados M, Chan KW. A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report from the Children's Oncology Group (CCG 9931). *Int J Radiat Oncol Biol Phys*. 2009 Apr 6 (Epub ahead of print).

Hervey-Jumper SL, Ziewacz JE, Heth JA, Sullivan SE. Frontal-to-temporal horn shunt as treatment for temporal horn entrapment. *J Neurosurg*. 2009 May 1 (Epub ahead of print).

Okauchi M, Hua Y, Keep RF, Morgenstern LB, Xi G. Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. *Stroke*. 2009 May; 40(5): 1858-63.

Orringer DA, Koo YE, Chen T, Kim G, Hah HJ, Xu H, Wang S, Keep R, Philbert MA, Kopelman R, Sagher O. In vitro characterization of a targeted, dye-loaded nanodevice for intraoperative tumor delineation. *Neurosurgery*. 2009 May; 64(5): 965-71; discussion 971-2.

Orringer DA, Koo YE, Chen T, Kopelman R, Sagher O, Philbert MA. Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. *Clin Pharmacol Ther*. 2009 May; 85(5): 531-4.

Snellings A, Sagher O, Anderson DJ, Aldridge JW. Identification of the subthalamic nucleus in deep brain stimulation surgery with a novel wavelet-derived measure of neural background activity. *J Neurosurg*. 2009 Apr 3 (Epub ahead of print).

## Obstetrics & Gynecology

Barber MD, Spino C, Janz NK, Brubaker L, Nygaard I, Nager CW, Wheeler TL; Pelvic Floor Disorders Network. The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. *Am J Obstet Gynecol*. 2009 May; 200(5): 580.

Brandon CJ, Lewicky-Gaupp C, Larson KA, Delancey JO. Anatomy of the perineal membrane as seen in magnetic resonance images of nulliparous women. *Am J Obstet Gynecol*. 2009 May; 200(5): 583.

Lewicky-Gaupp C, Hamilton Q, Ashton-Miller J, Huebner M, DeLancey JOL, Fenner DE. Anal sphincter structure and function relationships in aging and fecal incontinence. *Am J Obstet Gynecol*. 2009 May; 200(5): 559.

## Ophthalmology & Visual Sciences

Archer SM. Brown syndrome--operate or observe? *J Aapos*. 2009; 13(2): 115.

Banitt MR, Malta JB, Mian SI, Soong HK. Rupture of anterior lens capsule from blunt ocular injury. *J Cataract Refract Surg*. 2009; 35(5): 943-5.

Chong DY, Johnson MW, Huynh TH, Hall EF, Comer GM, Fish DN. Vitreous Penetration of Orally Administered Fanciclovir. *Am J Ophthalmol*. 2009 Apr 16 (Epub ahead of print).

Khanna H, Davis EE, Murga-Zamalloa CA, Estrada-Cuzcano A, Lopez I, den Hollander AI, Zonneveld MN, Othman MI, Waseem N, Chakarova CF, Maubaret C, Diaz-Font A, Macdonald I, Muzny DM, Wheeler DA, Morgan M, Lewis LR, Logan CV, Tan PL, Beer MA, Inglehearn CF, Lewis RA, Jacobson SC, Bergmann C, Beales PL, Attie-Bitach T, Johnson CA, Otto EA, Bhattacharya SS, Hildebrandt F, Gibbs RA, Koeneke RK, Swaroop A, Katsanis N. A common allele in RFGRIPL1 is a modifier of retinal degeneration in ciliopathies. *Nat Genet*. 2009 May 10 (Epub ahead of print).

Sugar A, Tanner JP, Dontchev M, Tennant B, Schultze RL, Dunn SP, Lindquist TD, Gal RL, Beck RW, Kollman C, Mannis MJ, Holland EJ. Recipient Risk Factors for Graft Failure in the Cornea Donor Study. *Ophthalmology*. 2009 Apr 22 (Epub ahead of print).

## Orthopaedic Surgery

Dougherty PJ, Vaidya R, Silverton CD, Bartlett C, Najibi S. Joint and Long-bone gunshot injuries. *Journal of Bone and Joint Surgery Am*. 2009; 91(4): 980-997.

Gibbs AE, Pickerman J, Sekiya JK. Weight Management in Amateur Wrestling. *Sports Health* 2009; 1(3): 227-230.

Lorincz C, Manske SL, Zernicke R. Bone Health: Part 1, Nutrition. *Sports Health* 2009; 1(3): 253-260.

Panaroni C, Gioia R, Lupi A, Besio R, Goldstein SA, Kreider J, Leikin S, Vera JC, Mertz EL, Perilli E, Baruffaldi F, Villa I, Farina A, Casasco M, Cetta G, Rossi A, Frattini A, Marini JC, Vezzoni P, Forlino A. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knock-in murine model for classical, dominant Osteogenesis Imperfecta. *Blood*. 2009 May 4 (Epub ahead of print).

Scibek, J.S., Carpenter, J.E., and Hughes, R.E. Rotator cuff tear pain and tear size and scapulohumeral rhythm. *Journal of Athletic Training*. 2009; 44(2): 148-159.

Uveges TE\*, Kozloff KM\*, Ty J, Ledgard F, Raggio CL, Gronowicz G, Goldstein SA, Marini JC. Alendronate treatment of Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. *Journal of Bone and Mineral Research*. 2009; 24(5): 849-859. \*Denotes co-first authors.

## Otolaryngology

Kanazawa T, Kommareddi PK, Iwashita T, Kumar B, Misawa K, Misawa Y, Jang I, Nair TS, Iino Y, Carey TE. Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells. *Clin Cancer Res*. 2009 Apr 1; 15(7): 2222-30.

Kommareddi PK, Nair TS, Vallurupalli M, Telian SA, Arts HA, El-Kashlan HK, Sataloff RT, Carey TE. Autoantibodies to recombinant human CTL2 in autoimmune hearing loss. *Laryngoscope*. 2009 May; 119(5): 924-32.

Misawa K, Ueda Y, Kanazawa T, Misawa Y, Jang I, Brenner JC, Ogawa T, Takebayashi S, Grenman RA, Herman JG, Mineta H, Carey TE. Epigenetic inactivation of GALR1 in head and neck cancer. *Clin Cancer Res*. 2008 Dec 1; 14(23): 7604-13.

Popovtzer R, Agrawal A, Kotov NA, Popovtzer A, Balter J, Carey TE, Kopelman R. Targeted gold nanoparticles enable molecular CT imaging of cancer. *Nano Lett* 2008 Dec; 8(12): 4593-6.

## Pathology

Glass WG, Argentieri RL, Bracht M, Farrell FX, Das AM, Del Vecchio AM, Hogaboam CM, Murray LA. Generation of bleomycin-induced lung fibrosis is independent of IL-16. *Cytokine*. 2009 Apr; 46(1): 17-23.

Ko MC, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Woods JH. Effects of cocaine esterase following its repeated administration with cocaine in mice. *Drug Alcohol Depend*. 2009 May 1; 101(3): 202-9.

Martins V, Valença SS, Farias-Filho FA, Molinaro R, Simões RL, Ferreira TP, R e Silva PM, Hogaboam CM, Kunkel SL, Fierro IM, Canetti C, Benjamim CF. ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. *J Immunol*. 2009 May 1; 182(9): 5374-81.

Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE Jr, Goleniewska K, Williams JV, Collins PL, Peebles RS Jr. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. *J Virol*. 2009 May; 83(9): 4185-94.

Mortaz E, Kraneveld AD, Smit JJ, Kool M, Lambrecht BN, Kunkel SL, Lukacs NW, Nijkamp FP, Folkerts G. Effect of cigarette smoke extract on dendritic cells and their impact on T-cell proliferation. *PLoS ONE*. 2009; 4(3): e4946.

O'Konek JJ, Boucher PD, Iacco AA, Wilson TE, Shewach DS. MLH1 deficiency enhances tumor cell sensitivity to ganciclovir. *Cancer Gene Ther*. 2009 Mar 20 (Epub ahead of print).

Raghavendran K, Notter RH, Davidson BA, Helinski JD, Kunkel SL, Knight PR. Lung Contusion: Inflammatory Mechanisms and Interaction with Other Injuries. *Shock*. 2009 Jan 19. (Epub ahead of print).

Rodriguez H, Snyder M, Uhlén M, Andrews P, Beavis RC, Borchers CH, Chalkley R, Cho SY, Cottingham K, Dunn M, Dylag T, Edgar R, Hare P, Heck AJ, Hirsch RF, Kennedy K, Kolar P, Kraus HJ, Mallick P, Nesvizhskii A, Ping P, Ponten F, Yang L, Vilar E, Mukherjee B, Kuick R, Raskin L, Misk DE, Taylor JM, Giordano TJ, Hanash SM, Fearon ER, Rennett

G, Gruber SB. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. *Clin Cancer Res*. 2009 Apr 15; 15(8): 2829-39.

Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, Fearon ER, Ljungman M, Simeone DM. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. *Cancer Cell*. 2009 Mar 3; 15(3): 207-19.

Wu J, Prindle MJ, Dressler GR, Yu X. PTIP regulates 53BP1 and SMC1 at the DNA damage sites. *J Biol Chem*. 2009 May 4 (Epub ahead of print).

Yates JR, Stein SE, Hermjakob H, Kinsinger CR, Apweiler R. Recommendations from the 2008 International Summit on Proteomics Data Release and Sharing Policy - A Summit Report. *J Proteome Res*. 2009 Apr 3 (Epub ahead of print).

## Pediatrics & Communicable Diseases

Adler J, Dickinson CJ. Thickened Formula is Only Moderately Effective in the Treatment of Gastroesophageal Reflux in Healthy Infants. *Pediatrics* 2008 Dec; 122(6): e1268-77.

Dempsey AF, Abraham LM, Dalton V, Ruffin M. Understanding Reasons why Mothers Do or Do Not Have Their Adolescent Daughters Vaccinated Against Human Papillomavirus. *Ann Epidemiol*. 2009 Apr 24 (Epub ahead of print).

Donn SM. Neonatal Ventilators: How do They Differ? *J Perinatol*. 2009 May; 29 Suppl 2: S73-8.

Kasa-Vubu JZ, Jain V, Welch K. Impact of Fatness, Insulin, and Gynecological age on Luteinizing Hormone Secretory Dynamics in Adolescent Females. *Fertil Steril*. 2009 Apr 24 (Epub ahead of print).

Kerlin BA, Blatt NB, Fuh B, Zhao S, Lehman A, Blanchong C, Mahan JD, Smoyer WE. Epidemiology and Risk Factors for Thromboembolic Complications of Childhood Nephrotic Syndrome: A Midwest Pediatric Nephrology Consortium (MWPNC) Study. *J Pediatr*. 2009 Apr 23 (Epub ahead of print).

Lopez-Duran NL, Hajal NJ, Olson SL, Felt BT, Vazquez DM. Individual Differences in Cortisol responses to Fear and Frustration During Middle Childhood. *J Exp Child Psychol*. 2009 Apr 30 (Epub ahead of print).

## Psychiatry

Arnold PD, MacMaster FP, Richter MA, Hanna GL, Sicard T, Burroughs E, Mirza Y, Easter PC, Rose M, Kennedy JL, Rosenberg DR. Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder. *Psychiatry Res: Neuroimaging*. 2009; 172: 136-139.

Kilbourne AM, Ignacio RV, Kim HM, Blow FC. Datapoints: are VA patients with serious mental illness dying younger?. *Psychiatr Serv*. 2009 May; 60(5): 589.

Perron BE, Mowbray OP, Glass JE, Delva J, Vaughn MG, Howard MO. Differences in service utilization and barriers among Blacks, Hispanics, and Whites with drug use disorders. *Subst Abuse Treat Prev Policy*. 2009 Mar 13; 4: 3.

Warden D, Rush AJ, Wisniewski SR, Lesser IM, Kornstein SG, Balasubramani GK, Thase ME, Preskorn SH, Nierenberg AA, Young EA, Shores-Wilson K, Trivedi MH. What predicts attrition in second step medication treatments for depression?: a STAR\*D Report. *Int J Neuropsychopharmacol*. 2009 May; 12(4): 459-73.

## Radiology

Bohnen NI, Müller ML, Kuwabara H, Constantine GM, Studenski SA. Age-associated leukoaraiosis and cortical cholinergic deafferentation. *Neurology*. 2009 Apr 21; 72(16): 1411-6.

Chen NG, Fowlkes JB, Carson PL, Schipper MJ, LeCarpentier GL. Rapid 3-D imaging of contrast flow: application in a perfused kidney phantom. *Ultrasound Med Biol*. 2009 May; 35(5): 813-28.

Fabiilli ML, Haworth KJ, Fakhri NH, Kripfgans OD, Carson PL, Fowlkes JB. The role of inertial cavitation in acoustic droplet vaporization. *IEEE Trans Ultrason Ferroelectr Freq Control*. 2009; 56(5): 1006-1017.

Haworth KJ, Fowlkes JB, Carson PL, Kripfgans OD. Generalized shot noise model for time-reversal in multiple-scattering media allowing for arbitrary inputs and windowing. *J Acoust Soc Am*. 2009 May; 125(5): 3129-40.

Yang Z, Sinha SP, Booi RC, Roubidoux MA, Ma B, Fowlkes JB, LeCarpentier GL, Carson PL. Breast ultrasound image improvement by pixel compounding of compression sequence. *IEEE Trans Ultrason Ferroelectr Freq Control*. 2009 Mar; 56(3): 465-73.

## Surgery

### General Surgery:

Basma H, Soto-Gutiérrez A, Yannam G, Liu L, Ito R, Yamamoto T, Ellis E, Carson S, Sato SD, Muirhead D, Navarro-Alvarez N, Wong R, Platt JL, Mercer DF, Miller JD, Strom SC, Kobayashi N, Fox JJ. Differentiation, Enrichment and Transplantation of Human ES Cell-Derived Hepatocytes. *Gastroenterology*. 2009; 136: 990-999.

Cascalho M, Ogle BM, Razonable RR, West LJ, Platt JL. Cardiac transplantation in infancy: A model for dissecting immunological function. *Journal of Paediatrics and Child Health*. 2008; 18(Suppl 1): 30-32.

Ghaferi AA, Wong SL, Johnson TM, Lowe L, Chang AE, Cimmino VM, Bradford CR, Rees, RS, Sabel MS. Prognostic Significance of a Positive Non-Sentinel Lymph Node in Cutaneous Melanoma. *Annals of Surgical Oncology*. 2009 (In press).

Ogle BM, Knudsen BE, Nishitai R, Ogata K, Platt JL. Toward development of human T cells in swine for potential use in adoptive T cell immunotherapy. *Tissue Engineering*. 2009; 15: 1031-1040.

Sabel, Michael S. *Surgical Foundations: Essentials of Breast Surgery*. Philadelphia: Elsevier; 2009.

Sihler KC and Hemmila M. Injuries in Non-Urban Areas are Associated with Increased Disability at Hospital Discharge. *Journal of Trauma*. 2009 (Accepted).

Wang Y, Wu R, Cho KR, Thomas DG, Gossner G, Liu JR, Giordano TJ, Shedden KA, Misek DE, Lubman DM. Differential Protein Mapping of Ovarian Serous Adenocarcinomas: Identification of Potential Markers for Distinct Tumor Stage. *J Prot Res*. 2009; 8: 1452-1463.

### Surgery Administration:

Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, Redman B, Welling TH, Chang A, Zou W. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. *Cancer Res*. 2009 May 1; 69(9): 3995-4000.

Kryczek I, Wei S, Szeliga W, Vatan L, Zou, W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. *Blood*, 2009 Mar 16 (Epub ahead of print) doi:10.1182/blood-2008-09-177360.

## Urology

Bloom DA, Scardino PT. Peter Lester Scardino--a genitourinary surgeon in third generation of the specialty: part 1. *Urology*. 2009 May; 73(5): 940-3.

Bloom DA, Scardino PT. Peter Lester Scardino--a genitourinary surgeon in third generation of the specialty: part 2. *Urology*. 2009 May; 73(5): 944-6.

Brenner JC, Chinnaiyan AM. Translocations in epithelial cancers. *Biochim Biophys Acta*. 2009 May 3 (Epub ahead of print).

Brubaker L, Stoddard A, Richter H, Zimmern P, Moalli P, Kraus SR, Norton P, Lukacz E, Sirls L, Johnson H; Urinary Incontinence Treatment Network. Mixed incontinence: comparing definitions in women having stress incontinence surgery. *Neurourol Urodyn*. 2009; 28(4): 268-73.

Calhoun EA, Clemens JQ, Litwin MS, Walker-Corkery E, Markossian T, Kusek JW, McNaughton-Collins M. Primary care physician practices in the diagnosis, treatment and management of men with chronic prostatitis/chronic pelvic pain syndrome. *Prostate Cancer Prostatic Dis*. 2009 Apr 7 (Epub ahead of print).

deVere White RW, Lara PN Jr, Goldman B, Tangen CM, Smith DC, Wood DP Jr, Hussain MH, Crawford ED. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). *J Urol*. 2009 Jun; 181(6): 2476-80; discussion 2480-1.

Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. *Mod Pathol*. 2009 May 1 (Epub ahead of print).

Hollenbeck BK, Ye Z, Dunn RL, Montie JE, Birkmeyer JD. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. *J Natl Cancer Inst*. 2009 Apr 15; 101(8): 571-80.

Hsiao AY, Torisawa YS, Tung YC, Sud S, Taichman RS, Pienta KJ, Takayama S. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. *Biomaterials*. 2009 Jun; 30(16): 3020-7.

Lee IH, Campbell CR, Song SH, Day ML, Kumar S, Cook DI, Dinudom A. The Activity of the Epithelial Sodium Channels Is Regulated by Caveolin-1 via a Nedd4-2-dependent Mechanism. *J Biol Chem*. 2009 May 8; 284(19): 12663-9.

Lucas N, Day ML. The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression. *J Cell Biochem*. 2009 Apr 15; 106(6): 967-74.

Markland AD, Richter HE, Kenton KS, Wai C, Nager CW, Kraus SR, Xu Y, Tennstedt SL; Urinary Incontinence Treatment Network. Associated factors and the impact of fecal incontinence in women with urge urinary incontinence: from the Urinary Incontinence Treatment Network's Behavior Enhances Drug Reduction of Incontinence study. *Am J Obstet Gynecol.* 2009 Apr; 200(4): 424.e1-8.

Parker WR, Montgomery JS, Wood DP Jr. Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner?. *Curr Opin Urol.* 2009 May; 19(3): 303-8.

Pelletier EM, Vats V, Clemens JQ. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. *Am J Manag Care.* 2009 Mar; 15(4 Suppl): S108-14.

Pienta KJ. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. *Urology.* 2009 May; 73(5 Suppl): S11-20.

Rozel S, Galbán CJ, Nicolay K, Lee KC, Sud S, Neeley C, Snyder LA, Chenevert TL, Rehemtulla A, Ross BD, Pienta KJ. Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. *J Cell Biochem.* 2009 May 1; 107(1): 58-64.

Shah RB, Chinnaiyan AM. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. *Adv Anat Pathol.* 2009 May; 16(3): 145-53.

Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin MA, Pienta KJ, Robins DM. Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy. *Cancer Res.* 2009 Apr 14 (Epub ahead of print).

Strope SA, Daignault S, Hollingsworth JM, Ye Z, Wei JT, Hollenbeck BK. Physician ownership of ambulatory surgery centers and practice patterns for urological surgery: evidence from the state of Florida. *Med Care.* 2009 Apr; 47(4): 403-10.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA. ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. *Eur Urol.* 2009 Apr 24 (Epub ahead of print).

Wang R, Morris DS, Tomlins SA, Lonigro RJ, Tsodikov A, Mehra R, Giordano TJ, Kunju LP, Lee CT, Weizer AZ, Chinnaiyan AM. Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. *Cancer Res.* 2009 May 1; 69(9): 3810-8.

Wang R, Wood DP Jr. Evolving role of renal biopsy in small renal masses. *Urol Oncol.* 2009 May-Jun; 27(3): 332-4.

Wheat JC, Wolf JS Jr. Advances in bioadhesives, tissue sealants, and hemostatic agents. *Urol Clin North Am.* 2009 May; 36(2): 265-75.

Wood DP Jr. When does lymphadenectomy improve survival of patients with genitourinary malignancies?. *J Urol.* 2009 Jun; 181(6): 2412-3.